Hims & Hers Stock Surge Amid FDA Regulatory Developments
Hims & Hers Health Inc. (HIMS) experienced a notable surge in its stock price for the second consecutive day, rising by 6% in early trading on Thursday. This uptick follows positive investor sentiment regarding potential changes from the Food and Drug Administration (FDA) related to certain peptides.
The company’s stock had already climbed 13% on Wednesday after the FDA announced plans to hold a meeting in July to evaluate the inclusion of seven peptides in the permissible substances list for compounding pharmacies like Hims & Hers. This regulatory shift is seen as a crucial milestone that could broaden the scope of treatments available from the company.
Health Secretary Robert F. Kennedy Jr. indicated in a social media post that the FDA is considering moving these peptides out of Category 2, a classification for drugs deemed too risky or unproven for compounding pharmacies. He expressed optimism that this decision could help combat black market demand by restoring regulated access.
Wall Street analysts view this FDA development positively. Hims & Hers, which acquired a peptide manufacturing facility in California last year, aims to expand its treatment offerings in areas such as weight loss and muscle recovery. Despite the recent gains, Hims & Hers stock remains down by 23% year-to-date, largely due to regulatory uncertainties surrounding the manufacturing of compounded GLP-1 weight-loss medications.
In a recent statement, Hims & Hers confirmed its commitment to providing GLP-1 customers with FDA-approved medication options and plans to offer compounded semaglutide on a limited basis through its platform.
Summary
In summary, the recent surge in Hims & Hers’ stock reflects positive market reactions to impending FDA evaluations of key peptides for compounding. This could enhance the company’s treatment portfolio while addressing regulatory concerns affecting its growth and stock performance. Despite current gains, Hims & Hers is still navigating challenges with regulatory risks and stock performance over the year.
Author: Ines Ferre
Senior Business Reporter at Yahoo Finance
Follow on X: @ines_ferre
